Loading clinical trials...

COMPLETEDPHASE2

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults With Atopic Dermatitis

NCT06723405•Evommune, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.

Detailed Description

This is a Phase 2a efficacy and safety study of intravenous EVO301 in adults with moderate to severe atopic dermatitis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Males or non-pregnant, non-lactating females, age 18 years or older
•2. Chronic atopic dermatitis for at least 6 months
•3. BSA of AD involvement of at least 10%
•4. EASI score of at least 16.

Exclusion Criteria

•1. Significant AD flare with 4 weeks
•2. Use of biologic therapy within 12 weeks
•3. Regular use of tanning booth within 4 weeks
•4. Skin condition that could interfere with study assessments

Locations (12)

Cornerstone Dermatology

Coorparoo, Australia

Momentum Clinical Research Darlinghurst

Darlinghurst, Australia

Pacific Clinical Research Network (PCRN) Auckland

Auckland, New Zealand

Optimal Clinical Trials North

Auckland, New Zealand

Optimal Clinical Trials

Auckland, New Zealand

Pacific Clinical Research Network (PCRN) Christchurch

Christchurch, New Zealand

Momentum Clinical Research Dunedin

Dunedin, New Zealand

Clinical Trials New Zealand Ltd

Hamilton, New Zealand

Momentum Clinical Research Lower Hutt

Hutt Central, New Zealand

Pacific Clinical Research Network (PCRN) Tasman

Nelson, New Zealand

Key Dates

Start Date

February 13, 2025

Primary Completion Date

November 17, 2025

Completion Date

November 17, 2025

Last Updated

December 4, 2025

Enrollment

ACTUAL participants

Conditions

Atopic Dermatitis (AD)EczemaEczema Atopic Dermatitis

Interventions

EVO301

BIOLOGICAL

Placebo

BIOLOGICAL

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395

Atopic Dermatitis (AD)

View study

RECRUITINGPHASE2

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT06096857

Atopic DermatitisEczema

View study

RECRUITINGPHASE1

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Inclusion Criteria

Exclusion Criteria

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Cardamom and Topical Roseomonas in Atopic Dermatitis

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma